Resources from the same session
Preclinical development of EGFR E20I inhibitors: Mechanisms of action
Presenter: P. A. Jänne, US
Session: Session 2 – EGFR E20I mutations inhibitor drug development
Resources:
Slides
Webcast
Phase I Clinical development of EGFR E20I inhibitors: Proof of principle studies
Presenter: S.H. Lee, KR
Session: Session 2 – EGFR E20I mutations inhibitor drug development
Resources:
Slides
Webcast
Presentation of clinical cases of patients with advanced NSCLC bearing EGFR E20I mutations: Considerations of access to diagnostics and molecular therapeutics
Presenter: A.M. C. Dingemans, NL
Session: Session 2 – EGFR E20I mutations inhibitor drug development
Resources:
Slides
Webcast